MARKET

IMMP

IMMP

Immutep
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7199
-0.0001
-0.01%
Closed 16:00 04/02 EDT
OPEN
0.6812
PREV CLOSE
0.7200
HIGH
0.7256
LOW
0.6500
VOLUME
224.28K
TURNOVER
--
52 WEEK HIGH
3.100
52 WEEK LOW
0.5300
MARKET CAP
2.80M
P/E (TTM)
-0.2310
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IMMP stock price target is 4.496 with a high estimate of 4.996 and a low estimate of 3.997.

EPS

IMMP News

More
  • TWO, ARI, GOGO and TTOO among midday movers
  • Seeking Alpha - Article · 03/25 16:42
  • Immutep down 45% premarket on underwhelming efti data
  • Seeking Alpha - Article · 03/25 10:55
  • Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020
  • GlobeNewswire · 03/25 02:35
  • Immuteps Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti
  • GlobeNewswire · 03/20 01:02

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About IMMP

Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.
More

Webull offers kinds of Immutep Ltd stock information, including NASDAQ:IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions.